Skip to main content

Peer Review reports

From: The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Original Submission
3 Jun 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
5 Jul 2022 Reviewed Reviewer Report
15 Jul 2022 Reviewed Reviewer Report
3 Aug 2022 Author responded Author comments - Xiangqian Su
Resubmission - Version 4
3 Aug 2022 Submitted Manuscript version 4
4 Aug 2022 Author responded Author comments - Xiangqian Su
Resubmission - Version 5
4 Aug 2022 Submitted Manuscript version 5
24 Aug 2022 Reviewed Reviewer Report
8 Oct 2022 Reviewed Reviewer Report
11 Oct 2022 Author responded Author comments - Xiangqian Su
Resubmission - Version 6
11 Oct 2022 Submitted Manuscript version 6
23 Oct 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
25 Oct 2022 Editorially accepted
28 Nov 2022 Article published 10.1186/s12885-022-10230-1

You can find further information about peer review here.

Back to article page